IRadimed vs Pulmonx
IRMD and LUNG side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How IRMD and LUNG compare
IRadimed is the larger company, worth 8.9 times as much as Pulmonx ($1.1B against $123M).
IRadimed grew revenue faster over the last twelve months (11.0% versus −3.2% for Pulmonx).
IRadimed keeps more of each dollar of sales as profit, with a net margin of 26.8% compared with −47.9% at Pulmonx.
IRadimed pays a dividend yielding 1.1%; Pulmonx does not pay one.
IRadimed scores higher on the StockData Score (19 against 6 for Pulmonx), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | IRMD | LUNG |
|---|---|---|
| Size and price | ||
| Market cap | $1.1B | $123M |
| Share price | $85.35 | $2.86 |
| Change, 1 year | −1.2% | 45.9% |
| Change, 5 years | 119% | −91.7% |
| Beta (5Y) | 0.75 | 1.73 |
| Employees | 166 | 296 |
| StockData Score | ||
| Total score | 19 (better) | 6 |
| Valuation score | 0 | 2 (better) |
| Growth score | 4 (better) | 2 |
| Performance score | 6 (better) | 1 |
| Health score | 6 (better) | 1 |
| Dividend score | 3 (better) | 0 |
| Valuation | ||
| P/E | 45.6× | – |
| P/S | 12.2× | 1.4× (better) |
| P/B | 10.3× | 3.6× (better) |
| EV/EBITDA | 33.7× | – |
| P/FCF | 41.8× | – |
| PEG | 2.32 | – |
| FCF yield | 2.4% (better) | −20.8% |
| Fair value | $53.46 | $4.74 |
| Margin of safety | −59.7% | 39.7% (better) |
| Growth | ||
| Revenue growth (TTM) | 11.0% (better) | −3.2% |
| Revenue growth, 5Y average | 21.5% | 22.6% (better) |
| Net income growth (TTM) | 13.2% | – |
| EPS growth (TTM) | 13.3% | – |
| EPS growth, 5Y average | 73.9% | – |
| Profitability | ||
| Gross margin | 75.5% | 77.4% (better) |
| Operating margin | 32.3% (better) | −44.4% |
| Net margin | 26.8% (better) | −47.9% |
| FCF margin | 29.3% (better) | −28.8% |
| Return on equity | 23.4% (better) | −90.3% |
| Return on invested capital | 52.3% (better) | −156% |
| Financial health | ||
| Debt / equity | 0.00 | 1.11 (better) |
| Interest coverage | – | −9.4× |
| Current ratio | 8.99 (better) | 4.05 |
| Altman Z-score | 48.00 (better) | −5.75 |
| Piotroski F-score | 6 (better) | 3 |
| Dividends and buybacks | ||
| Dividend yield | 1.1% | – |
| Payout ratio | 67.6% | – |
| Shareholder yield | 1.1% (better) | 0.00% |
| Ownership | ||
| Held by institutions | 61.4% | 61.0% |
| Held by insiders | 35.5% | 16.6% |
| Insider net buying, 12 months | −$16.0M | −$548K (better) |
| Short interest, % of float | 7.2% | 2.2% |
Go deeper
- IRMD stock overview
- IRMD income statement
- IRMD valuation and score
- LUNG stock overview
- LUNG income statement
- LUNG valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.